‘Not guinea pigs': Indonesian officials debunk rumours, defend safety of Bill Gates-backed TB vaccine trial
Controversy, including reported rumours and misinformation surrounding the M72/AS01E vaccine candidate, arose after Indonesian President Prabowo Subianto's remarks following his meeting with American philanthropist and Gates in Indonesia on May 7.
Prabowo said Gates was 'developing a TB vaccine for the world' and that Indonesia would be 'one of the places to test' the vaccine.
The president also praised Gates' contributions to the country, noting that his foundation had provided more than US$159 million in grants since 2009, mostly for health programmes.
However, in the wake of Prabowo's comments, netizens expressed doubts about Indonesia being the 'testing ground' for the vaccine candidate. They questioned Gates' intention and why it was only being tested in 'poor countries'.
Indonesia is the only country outside Africa to take part in the trial.
VACCINE CANDIDATE IS SAFE: INDONESIAN AUTHORITIES
Participating in the trial means Indonesians will be among the first to receive the TB vaccine, said Taruna Ikrar, head of the country's Food and Drug Supervisory Agency (BPOM), on Wednesday (May 14), as reported by news agency Antara.
Vaccination is one of the most effective strategies to reduce TB prevalence in the country, he said. According to the World Health Organization (WHO), the estimated incidence of TB in Indonesia was 387 per 100,000 population in 2023.
Indonesia sees over 1 million TB cases a year and was estimated to have the world's second-highest number of TB cases in 2023, after India.
It accounted for 10 per cent of an estimated 10.8 million cases globally in 2023, according to the WHO's Global TB Report 2024. Indonesia recorded about 125,000 deaths from TB in 2023, according to Taruna.
TB is an airborne infectious disease caused by a bacterium called Mycobacterium tuberculosis, and primarily affects the lungs. It can cause lung damage or death if untreated.
The WHO has called M72 the most advanced TB vaccine candidate in development.
Taruna said the vaccine to be trialled is safe, having undergone pre-clinical testing, toxicity studies and safety trials in line with international standards.
'Based on scientific evaluations, we have authorised the clinical trials of the TB vaccine in Indonesia,' he told Antara. 'There is no issue here. The TB vaccine will bring many benefits.'
Health Minister Budi Gunadi Sadikin also assured the vaccine is safe.
'This is to educate the public, as well, that we are not guinea pigs,' he reportedly said on May 9.
Rumours about the vaccine were 'intentionally spread so that people do not want to be vaccinated. In fact, the consequences can be very fatal, 100,000 people could die because of something like this,' Budi said on May 9.
On Wednesday, Budi said the trial will help determine the vaccine's compatibility with Indonesia's population, as vaccine effectiveness can depend on genetic factors, reported news outlet Tempo.
He said the trial involves scientists at Padjadjaran University and the University of Indonesia.
If successful, Indonesia could eventually serve as a manufacturing site for the vaccine, he said.
INDONESIA INVOLVED IN TB VACCINE TRIAL SINCE 2024
The M72 is developed by pharmaceutical firm GlaxoSmithKline in partnership with AERAS, a United States-based not-for-profit funded by the Bill and Melinda Gates Foundation and other organisations.
Indonesia's involvement in the late-stage trial has been known since last year.
New vaccines are urgently needed to tackle TB in Indonesia and globally, the WHO said in a news release in November 2024 when it convened the first national consultation on new TB vaccines together with Indonesia's Ministry of Health in Bali.
The last TB vaccine was approved over 100 years ago.
If M72's efficacy is confirmed in the late-stage trial, it could lead to the introduction of a new TB vaccine for adults and adolescents by 2030, said the WHO.
The Phase 3 trial involves 20,000 participants from five countries.
Besides the 2,095 people from Indonesia, the rest are from South Africa, Kenya, Malawi and Zambia. Africa had the second-highest number of TB cases in 2023 after Southeast Asia, according to the Global TB Report 2024.
The earlier Phase 2b of the trial involved more than 3,500 people in South Africa, Zambia and Kenya, and results were 'cautiously encouraging', reported an article on May 13 by Gavi, the Vaccine Alliance, a global health partnership.
'In these adults, who were already thought to have been infected with the bacterium (TB bacteria can remain dormant for many years), the vaccine halved the risk of developing active TB over the next three years compared to a placebo, with an estimated efficacy of 50 per cent,' it reported.
The rumours circulating in Indonesia about M72 is not the first time that conspiracy theories related to public health and Gates have arisen in Indonesia.
In 2023, misinformation about Wolbachia mosquitoes stoked protests and delayed the rollout of a project in Bali that involved their release to fight dengue. The project involved the World Mosquito Programme, which is supported by the Bill and Melinda Gates Foundation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNA
2 hours ago
- CNA
Heat stress: Land transport infrastructure sector employers urged to adopt heat measures
Authorities are urging the land transport infrastructure sector to step up heat-stress management, as temperatures rise with climate change. Their latest guidelines build on earlier measures for outdoor work, and cover workers involved in road works and related activities. Professor Marcus Ong, Senior Consultant at the Department of Emergency Medicine at the Singapore General Hospital, examines if these measures are enough. He also puts forward his own proposed recommendations.
CNA
8 hours ago
- CNA
Demand for home hospice services rising faster than manpower, say providers
SINGAPORE: When 86-year-old Paul Wong was diagnosed with terminal stomach cancer in January, he chose to spend the rest of his days in the comfort of his home. A year ago, his wife passed away from colorectal cancer at home with the support of Assisi Hospice's hospice home care service. 'I saw the care she received and I hope would be able to receive that too,' he told CNA. 'I've stayed here for over 40 years. I find the place quiet, and the neighbours are friendly. I hope to be comfortable and manage my pain.' His daughter and grandchildren also live nearby and visit him for meals and activities. Mr Wong is among a growing number in Singapore opting for palliative support at home. They have also gotten a boost from the government, which is looking to increase the availability of such end-of-life care. To help more people spend their final days the way they wish to, the Ministry of Health (MOH) has put in place a National Strategy for Palliative Care. Since its launch in 2023, home palliative care capacity has grown by 25 per cent, from 2,400 to 3,000 places. It is set to increase to 3,600 places by the end of this year. An equipment rental scheme that was put in place, which provides patients with subsidised essentials like hospital beds, has benefited more than 1,000 Singaporeans so far. Care providers said it is not just about infrastructure, but also having competent palliative care staff – and there is a shortage. HIRING STRUGGLES In fact, demand for such care is rising faster than manpower, with providers saying they need more trained staff to keep up. HCA Hospice Care, the nation's largest home hospice provider, said hiring is an ongoing issue. "One of the things I struggle with is to find the right people with the right heart to do this work,' said its medical director Dr Chong Poh Heng. 'It's not a terribly glamorous (job) to work in the home, in different settings, some of which are, in my opinion, not quite habitable,' Dr Chong added. 'But the patient is comfortable there, so within those limitations (we must) find the means to deliver the same quality of care to those patients and their families." The hospice looks after about 1,400 home patients and will soon increase capacity to take in more. Among its ways to manage manpower issues is enlisting the help of the patients' caregivers. "We teach (caregivers) some of the knowledge aspects, including hands on (care), hygiene care, serving of medication, sometimes giving injections too,' said Dr Chong. Family members also learn to prepare special food and manage appliances like oxygen concentrators or suction machines, he added. TRAINING TAKES YEARS One challenge in hiring is finding personnel with adequate skills and qualifications, as roles in the sector can take years to learn. Assisi Hospice said its staff nurses are trained for up to three years before they are fully competent and can deliver care effectively. It is the largest inpatient facility in Singapore, and is leveraging home care to meet growing demand. Its home caseload has grown nearly five-fold over the last decade to about 700 today. The figure is projected to reach 850 by late 2026. Aside from medical know-how, staff also need training to understand how to manage the mental and psychosocial needs of the patients and their families. 'Palliative care patients (are) very ill, with many comorbidities, different organs may not be functioning. They have been through a lot,' said the hospice's CEO Choo Shiu Ling. 'Their journey in the healthcare system would have been very long. They have a high complexity of needs. Their caregivers could be emotionally and financially exhausted,' she added. 'It is the nurses and the special skills of a palliative care team that can possibly address all these very complex (issues).' She said the hospice's priority is to train its healthcare staff well and continue to grow its home care team. 'Because we discover (that) when nurses are confident and competent, it aids retaining so they stay with us, and we actually have a very low or almost no attrition for our home care team,' noted Ms Choo. Assisi Hospice currently has 48 staff tending to end-of-life patients at home, and plans to grow the team to 60 by the end of next year. There are around nine providers in Singapore that specialise in home palliative care. The sector needs at least 20 to 30 per cent more home hospice staff as the population ages, warned the Singapore Hospice Council. Board member Mervyn Koh suggested adequate remuneration and recognition could attract more to the industry. With funding another key concern as home hospice is fully subsidised, he said he also expects such care to be chargeable in future. 'Chargeable doesn't mean expensive. If it is MediSave deductible, that may be the way to go in future to keep healthcare costs sustainable,' said Dr Koh, who is also a senior consultant of palliative medicine at Tan Tock Seng Hospital. 'This will enable families to still (fulfil) the wishes of patients passing on at home without having to fork out cash by themselves.' He pointed out that most home hospice care providers are charity organisations, and it may be challenging to keep up free home care due to rising costs. "Policy makers can consider potentially opening up, say, MediShield Life to support home hospice care,' Dr Chong said. 'Currently, it can be used in the hospital, in inpatient hospice facilities, but it's not quite possible to use MediShield or insurance to pay for home care."
CNA
12 hours ago
- CNA
Cordlife sets aside S$500,000 for enhanced compensation package to affected customers
SINGAPORE: Cordlife has set aside S$500,000 (US$389,500) for an enhanced compensation package for affected customers following its mishandling of cord blood units. In a regulatory filing on its financial results for the first half of 2025, the private cord blood bank said late on Thursday (Aug 14) that the compensation package formed part of several one-off costs recorded for the first six months of the year. Cordlife added that it had also incurred S$200,000 in costs related to the testing of more than 200 samples of cord blood units (CBU) from five storage tanks deemed by the Ministry of Health (MOH) to be at "low risk" of being adversely affected. The company agreed to the testing in April 2024, which it said would take approximately a year to complete, before reviewing the results with MOH experts. In an update on Thursday, Cordlife said the "comprehensive and independent" review is expected to be completed in or around the later part of 2025. As part of the enhanced package, announced on Jul 10, affected customers will have their existing cord blood storage period extended - at no additional cost - until their child turns 26. The package was announced after Cordlife held a series of online and in-person townhalls in late June to engage with affected customers. It has since expanded the warranty clause to cover more situations. If the stored cord blood unit is needed by the donor or a biological sibling (and it is a suitable match) but cannot be used for an approved stem cell transplant because it does not meet the required quality standards - and if the company also cannot find a suitable replacement cord blood unit - it will pay the affected customer S$50,000. In June, Cordlife said in a regulatory filing that around 56 per cent of affected Cordlife customers had accepted refund offers made by the company. The offers comprised a refund of the annual fees paid by affected clients from the onset of the "temperature excursion". Its mishandling of cord blood units was first made public on Nov 30, 2023, when MOH revealed that investigations were ongoing. Seven tanks storing cord blood units were exposed to temperatures above acceptable limits. About 2,200 cord blood units were found damaged in one of the tanks, affecting at least 2,150 clients. In April last year, it was announced that another 5,300 cord blood units in a second tank and dry shipper were deemed "non-viable". LETTERS OF DEMAND Some affected customers have decided to take legal action against the company. In a separate bourse update on the matter on Thursday, Cordlife said it had received on Jul 31 a letter of demand from a law firm acting for a group of affected clients. This group is claiming damages for breach of contract and negligence. The company added that total customer claims amount to about S$8.7 million, representing less than 10 per cent of its net asset value as of Jun 30. Cordlife previously said it had received on Mar 28 two letters of demand from lawyers acting for two groups of affected clients. One of the groups is claiming damages for breach of contract and negligence, while the other group is requesting compensation for costs, among other warranties and undertakings from Cordlife. The company received its first letter of demand in May last year, while two other announcements were made on Aug 15, 2024 and Mar 1 on the same matter. ACCREDITATION, IMPROVED FINANCIALS Cordlife also said on Thursday it is working closely with the Association for the Advancement of Blood & Biotherapies (AABB) and the Foundation for the Accreditation of Cellular Therapy (FACT) to restore its accreditations for its Singapore operations. In December 2023, it lost its cellular therapy accreditation with FACT. The suspension will last indefinitely, "at a minimum until FACT's investigations are completed and issues are resolved", Cordlife then said. AABB followed suit in August last year, with the international blood bank body withdrawing Cordlife's accreditation for the collection, processing, storage and distribution of cord blood. On its financial results for the first half of this year, the company reported revenue of S$19.4 million - more than double the S$9.2 million it earned in the same period last year. Cordlife mainly attributed the increase in revenue to the full resumption of Singapore operations in January, after being suspended for almost nine months. The company's gross profit also rose to S$10.9 million in the first half of 2025, up from S$1.4 million in the corresponding period a year ago. Cordlife said it remains "cautiously optimistic" that financial performance will improve, driven by the resumption of Singapore operations, ongoing efforts at actively addressing outstanding issues and the "long-term growth potential" of the cord blood banking industry. Said Cordlife group CEO and executive director Chen Xiaoling: 'We continue to see new business opportunities, and have been investing in our sales and marketing efforts to restore customer confidence and grow our sales pipeline back to pre-incident levels.
